Peter Borchmann

614 total citations
6 papers, 11 citations indexed

About

Peter Borchmann is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Peter Borchmann has authored 6 papers receiving a total of 11 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 1 paper in Neurology. Recurrent topics in Peter Borchmann's work include Lymphoma Diagnosis and Treatment (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and CAR-T cell therapy research (3 papers). Peter Borchmann is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and CAR-T cell therapy research (3 papers). Peter Borchmann collaborates with scholars based in Germany, United States and Australia. Peter Borchmann's co-authors include Colm Keane, David Lavie, Abraham Avigdor, John M. Timmerman, Vladan Vučinić, Nathalie A. Johnson, Alex F. Herrera, Gareth P. Gregory, Richard Greil and Karolin Trautmann‐Grill and has published in prestigious journals such as Blood and Hematological Oncology.

In The Last Decade

Peter Borchmann

5 papers receiving 11 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Borchmann Germany	3	8	8	3	3	2	6	11
Trisha Mandal India	2	9 1.1×	8 1.0×	2 0.7×	3 1.0×		5	10
Daryl Ming Zhe Cheah Singapore	2	13 1.6×	9 1.1×	5 1.7×	3 1.0×		3	15
Cécile Leyronnas France	3	7 0.9×	14 1.8×	5 1.7×	3 1.0×		4	22
Alba Cabirta Spain	3	7 0.9×	6 0.8×	4 1.3×	6 2.0×	1 0.5×	9	14
Spencer Henick Bachow United States	2	6 0.8×	4 0.5×	2 0.7×	4 1.3×		2	9
Giovanni Paolo Maria Zambrotta Italy	2	9 1.1×	9 1.1×	3 1.0×	5 1.7×		4	15
William Honeycutt United States	3	14 1.8×	5 0.6×	2 0.7×	6 2.0×	1 0.5×	4	17
Suzanne Allibone United States	2	14 1.8×	10 1.3×	4 1.3×	3 1.0×		2	16
Aurora Taira Finland	4	7 0.9×	4 0.5×	3 1.0×	1 0.3×		6	38
José J. Rifón Roca Spain	2	5 0.6×	9 1.1×	1 0.3×	2 0.7×	1 0.5×	4	11

Countries citing papers authored by Peter Borchmann

Since Specialization

Citations

This map shows the geographic impact of Peter Borchmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Borchmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Borchmann more than expected).

Fields of papers citing papers by Peter Borchmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Borchmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Borchmann. The network helps show where Peter Borchmann may publish in the future.

Co-authorship network of co-authors of Peter Borchmann

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Borchmann. A scholar is included among the top collaborators of Peter Borchmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Borchmann. Peter Borchmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Borchmann, Peter, Dennis A. Eichenauer, Gerard Frigola, & Elı́as Campo. (2025). Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment. Hematological Oncology. 43(S2). e70080–e70080. 1 indexed citations

2.

Bröckelmann, Paul J., Josée M. Zijlstra, Stephan Mathas, et al.. (2024). Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial. Blood. 144(Supplement 1). 4428–4428.

3.

Johnson, Nathalie A., David Lavie, Peter Borchmann, et al.. (2023). Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. Blood. 142(Supplement 1). 1693–1693. 3 indexed citations

4.

Santoro, Armando, Nathalie A. Johnson, Kerry J. Savage, et al.. (2023). Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study. Blood. 142(Supplement 1). 1725–1725. 1 indexed citations

5.

Johnson, Nathalie A., David Lavie, Peter Borchmann, et al.. (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Blood. 140(Supplement 1). 6540–6542. 2 indexed citations

6.

Timmerman, John M., David Lavie, Nathalie A. Johnson, et al.. (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment. Blood. 140(Supplement 1). 768–770. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact